The FDA approved Cubist Pharmaceuticals Inc.'s first-in-class antibiotic, Cubicin, for infections caused by Gram-positive bacteria. (BioWorld Today)

The FDA approved Cubist Pharmaceuticals Inc.'s first-in-class antibiotic, Cubicin, for infections caused by Gram-positive bacteria. (BioWorld Today)

Without the benefit of full data on a 771-patient Phase III trial, Wall Street remained a little wary about results released Wednesday by Genta Inc. and partner Aventis SA on Genasense, an antisense oncology compound being studied in malignant melanoma. (BioWorld Today)

Without the benefit of full data on a 771-patient Phase III trial, Wall Street remained a little wary about results released Wednesday by Genta Inc. and partner Aventis SA on Genasense, an antisense oncology compound being studied in malignant melanoma. (BioWorld Today)

An FDA panel of experts voted in favor of Raptiva, a humanized monoclonal antibody made by Genentech Inc. and XOMA Ltd. for the treatment of moderate to severe plaque psoriasis in adults. (BioWorld Today)

An FDA panel of experts voted in favor of Raptiva, a humanized monoclonal antibody made by Genentech Inc. and XOMA Ltd. for the treatment of moderate to severe plaque psoriasis in adults. (BioWorld Today)